It has been reported that ARF1 may activate the ERK pathway in breast cancer 19 and induce cell adhesion-mediated drug resistance by activating AKT and ERK signaling in multiple myeloma cells 17. This evidence concerns the gene AKT1 and plasma cell myeloma.